Dashboard
Portfolios
Watchlist
Community
Discover
Screener
Narratives
Your Valuation
Community
/
United States
/
Pharmaceuticals & Biotech
Create a narrative
Illumina Community
NasdaqGS:ILMN Community
2
Narratives
written by author
0
Comments
on narratives written by author
59
Fair Values set
on narratives written by author
Create a narrative
Illumina
Popular
Undervalued
Overvalued
Community Investing Ideas
Illumina
AN
AnalystHighTarget
Consensus Narrative from 25 Analysts
NovaSeq X And Multiomics Focus Will Unlock Opportunities
Key Takeaways Focus on new innovations and NovaSeq X system to drive substantial revenue growth and expand into the broader genomics market. Partnership with NVIDIA for AI-driven data analysis is set to enhance informatics solutions, attracting more customers.
View narrative
US$151.26
FV
50.4% undervalued
intrinsic discount
4.92%
Revenue growth p.a.
Set Fair Value
0
users have liked this narrative
0
users have commented on this narrative
0
users have followed this narrative
1 day ago
author updated this narrative
Illumina
AN
AnalystConsensusTarget
Consensus Narrative from 25 Analysts
Will Focus On Multiomics And AI Partnerships To Strengthen Future Prospects
Key Takeaways Illumina's strategic innovations and multiomic focus aim to drive revenue growth and diversify earnings. Partnerships and operational efficiencies may bolster expansion and cost savings despite geopolitical challenges in China.
View narrative
US$126.80
FV
40.8% undervalued
intrinsic discount
3.34%
Revenue growth p.a.
Set Fair Value
0
users have liked this narrative
0
users have commented on this narrative
33
users have followed this narrative
6 days ago
author updated this narrative
Your Valuation for
ILMN
ILMN
Illumina
Your Fair Value
US$
Current Price
US$75.06
21.1% undervalued
intrinsic discount
Growth estimate over
Annual revenue growth rate
5 Years
time period
%/yr
Decrease
Increase
Past
Future
-4b
5b
2015
2018
2021
2024
2025
2027
2030
Revenue US$5.4b
Earnings US$663.9m
Advanced
Set Fair Value